Migraine
A Managed Access Protocol (MAP) is in place for medicines for the management of episodic and chronic migraine. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of atogepant, erenumab, fremanezumab, galcanezumab or rimegepant under the High Tech Arrangement, or eptinezumab under Hospital Pricing Approval.
Applications for reimbursement approval for atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab and rimegepant for the management of episodic and chronic migraine under the High Tech Arrangement/ Hospital Pricing Approval will only be considered from consultant neurologists registered with the Irish Medical Council, who have agreed to the terms of this MAP and have been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for Medicines for the Management of Episodic and Chronic Migraine can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.